Simcere Pharmaceutical Group (NYSE:SCR)

lareineivre (75.70) Submitted: 12/30/2007 2:48:23 AM : Start Price: $13.18 SCR Score: -28.87

Favorable risk / reward profile. Comparative analysis:
http://f1.grp.yahoofs.com/v1/8EF3R8IApDlbI1SUEwj9ACPoO-N506V3BymU7tTVdt21_4PxNLCn-oJ6KY_K8iQ5Z-yn652fM-b9S1MpHcVrFg/VOps/VOps%2007.11.30.xls

Durrett1081 (35.27) Submitted: 11/5/2007 11:10:37 PM : Start Price: $15.40 SCR Score: -36.35

I consider this one a high risk with huge upside potential.

hennessy7 (< 20) Submitted: 10/2/2007 10:45:01 AM : Start Price: $16.61 SCR Score: -38.50

goldman sachs china buy

patricktalk (< 20) Submitted: 5/28/2007 4:50:14 PM : Start Price: $16.10 SCR Score: -38.94

Endo, a patented cancer drug, sells at US$150 per tube in China. Each patient recommends to have 14x5=60 tubes per treatment. it adds up to $9,000 per patient. According to the statistic, there are about 2 millions cancer patients in China last year, let's suppose to have 1% cancer population treated with Endo. Estimated revenue will sum up to 9,000 milions US dollow income potencially as long as production capacity can catch up those number

whampoafn (79.44) Submitted: 5/16/2007 9:00:55 PM : Start Price: $16.01 SCR Score: -38.98

owns a patented cancer drug, which is rare in China and a portfolio of products that are well suite to China's exploding domestic market.